Masimo announces strategic investment totaling $3.5M in SEDLine

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, today announced a strategic investment totaling $3.5 million in SEDLine, Inc., a newly-formed private company that was formerly operated by Hospira, Inc. Under terms of the investment agreement, Masimo may increase its investment subject to certain financial and development milestones. SEDLine's mission is to expand the scope and applications for neuromonitoring. Masimo's investment will allow SEDLine to continue to support its existing customers, market to new customers, and expand its research and development efforts.

Masimo Chairman and CEO, Joe Kiani, stated, "Multiple leading hospitals in the United States have already chosen SEDLine because they believe, as Masimo does, that SEDLine's current technology is better than competitive brain function monitoring technologies. Masimo has always been a strong advocate for innovation, patient care, and providing choice in the marketplace, so we are happy to become an investor in SEDLine's continued commercial availability and support this new entity in their goal to enhance and expand the applications for brain function monitoring."